- Home
- IRWD vs RIGL Comparison
IRWD vs RIGL Comparison
Compare IRWD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IRWD | RIGL |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.6M | 537.6M |
| IPO Year | 2010 | 2000 |
Fundamental Metrics
Financial Performance| Metric | IRWD | RIGL |
|---|---|---|
| Price | $3.32 | $42.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.34 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 2.3M | 560.9K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 0.18 | ★ 6.20 |
| Revenue | ★ $338,987,000.00 | $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $4.01 | $0.22 |
| P/E Ratio | $19.03 | ★ $6.91 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $0.53 | $15.50 |
| 52 Week High | $4.78 | $52.24 |
Technical Indicators
Market Signals| Indicator | IRWD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 50.92 |
| Support Level | $3.11 | $41.54 |
| Resistance Level | $3.39 | $44.85 |
| Average True Range (ATR) | 0.20 | 1.73 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 36.36 | 57.97 |
Price Performance
Historical ComparisonAbout IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.